Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study.

医学 中期分析 临床终点 内科学 化疗 安慰剂 肺癌 阶段(地层学) 围手术期 肿瘤科 外科 随机化 非小细胞肺癌 临床试验 病理 古生物学 替代医学 生物 A549电池
作者
Shun Lü,Lin Wu,Wei Zhang,Peng Zhang,Wenxiang Wang,Wentao Fang,Wenqun Xing,Qixun Chen,Jiandong Mei,Lin Yang,Lijie Tan,Xiaokang Sun,Shidong Xu,Xiaohua Hu,Guohua Yu,Dongliang Yu,Jinlu Shan,Nong Yang,Yuping Chen,Hui Tian
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:41 (16_suppl): 8501-8501 被引量:15
标识
DOI:10.1200/jco.2023.41.16_suppl.8501
摘要

8501 Background: Adjuvant and neoadjuvant immunotherapy have been approved by US FDA to treat early-stage NSCLC. However, the optimal neoadjuvant and adjuvant treatment, including duration of treatment, are unknown. We present the interim results of a randomized, double-blind, placebo-controlled, Phase III trial to evaluate the efficacy and safety of perioperative toripalimab plus chemotherapy followed by toripalimab maintenance vs chemotherapy in resectable stage III NSCLC. Methods: Patients with stage II/III resectable NSCLC, without EGFR/ALK alterations for non-squamous NSCLC, were randomized 1:1 to receive 240 mg toripalimab or placebo combined with chemotherapy Q3W for 3 cycles before surgery and one cycle after surgery, followed by toripalimab or placebo monotherapy Q3W for 13 cycles. Stratification variables for randomization included disease stage, histopathologic subtype, PD-L1 expression and surgical procedure. Primary endpoints were EFS by investigator and major pathological response (MPR) rate by a blinded independent pathologic review (BIPR) in the stage III and the ITT populations. Secondary endpoints included overall survival (OS), pathologic complete response (pCR) rate, EFS by independent review committee (IRC), and safety. A planned interim analysis was performed on the primary endpoint of EFS in the stage III subjects. Results: A total of 404 stage III NSCLC patients were randomized to toripalimab (n=202) or placebo (n=202). By the data cutoff date (November 30, 2022), the median follow-up was 18.3 months. Baseline characteristics were well balanced between the two arms. EFS was significantly improved in the toripalimab arm, HR=0.40, 95% CI (0.277-0.565), P<0.0001, and crossed the pre-specified efficacy boundary. The median EFS was not reached in the toripalimab arm and 15.1 months in the placebo arm. A consistent effect on EFS, favoring toripalimab, was observed in all subgroups. The MPR and pCR rates per BIPR were also higher in the toripalimab arm, 48.5% vs 8.4% and 24.8% vs 1.0%, respectively. The OS results showed a trend favoring toripalimab. The incidence of Grade ≥3 adverse events (AEs) (63.4% vs 54.0%), fatal AEs related to toripalimab/placebo (0.5% vs 0%) and AEs leading to discontinuation of toripalimab/placebo (9.4% vs 7.4%) were comparable between the two arms. However, the incidence of immune-related AEs (42.1% vs 22.8%) was more frequent in the toripalimab arm. Conclusions: The addition of toripalimab to perioperative chemotherapy showed statistically significant improvements in EFS for stage III NSCLC patients with a manageable safety profile. Patients will be followed for overall survival. Clinical trial information: NCT04158440 .
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
臧为完成签到,获得积分10
刚刚
刚刚
共享精神应助杰尼龟采纳,获得10
1秒前
Aminoacid完成签到,获得积分10
2秒前
3秒前
TMOMOR举报懒洋洋求助涉嫌违规
3秒前
ggg完成签到,获得积分10
3秒前
毕春宇完成签到,获得积分10
3秒前
毛毛完成签到,获得积分10
4秒前
在水一方应助JIE采纳,获得10
4秒前
刘Liam完成签到 ,获得积分10
4秒前
淡然宛凝完成签到 ,获得积分10
5秒前
天天读文献完成签到,获得积分10
5秒前
Aminoacid发布了新的文献求助10
6秒前
炸药发布了新的文献求助10
6秒前
北欧海盗完成签到,获得积分10
6秒前
张三完成签到 ,获得积分10
7秒前
标致玉米发布了新的文献求助10
7秒前
FashionBoy应助阿达西采纳,获得10
8秒前
多情的灵安完成签到,获得积分10
8秒前
lmj717完成签到,获得积分10
8秒前
南城花开完成签到 ,获得积分10
8秒前
8秒前
9秒前
豆豆完成签到,获得积分10
9秒前
酷波er应助云襄采纳,获得10
10秒前
做实验一点都不酷完成签到,获得积分10
10秒前
猫的毛完成签到 ,获得积分10
11秒前
王铂然完成签到,获得积分10
11秒前
11秒前
TheSilencer完成签到 ,获得积分10
12秒前
可怜的小羊完成签到,获得积分10
12秒前
江中完成签到 ,获得积分10
12秒前
无心的天真完成签到 ,获得积分10
12秒前
kxy完成签到,获得积分10
12秒前
淡定的安白完成签到,获得积分10
12秒前
波里舞完成签到 ,获得积分10
12秒前
12秒前
鲍binyu完成签到,获得积分10
13秒前
东北饿霸完成签到,获得积分10
13秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968608
求助须知:如何正确求助?哪些是违规求助? 3513486
关于积分的说明 11168243
捐赠科研通 3248926
什么是DOI,文献DOI怎么找? 1794540
邀请新用户注册赠送积分活动 875188
科研通“疑难数据库(出版商)”最低求助积分说明 804676